Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-11-17
1999-11-16
Ford, John M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31435
Patent
active
059858885
ABSTRACT:
Camptothecin compounds having a --CH.sub.2 --L group are effective anti-tumor compounds. These compounds inhibit the enzyme topoisomerase I and DNA of associated topoisomerase I-DNA complexes.
REFERENCES:
patent: 5004758 (1991-04-01), Boehm et al.
patent: 5342947 (1994-08-01), Lackey
patent: 5496235 (1996-03-01), Shapiro et al.
patent: 5559235 (1996-09-01), Luzzio et al.
patent: 5646159 (1997-07-01), Wall et al.
patent: 5734056 (1998-03-01), Burk et al.
patent: 5756512 (1998-05-01), Johnson
Wall et al. J. Med. Chem vol. 36, pp. 2689-2700, 1993.
Wall Monroe E.
Wani Mansukh C.
Ford John M.
Research Triangle Institute
LandOfFree
Camptothecin compounds with combined topoisomarase I inhibition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Camptothecin compounds with combined topoisomarase I inhibition , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Camptothecin compounds with combined topoisomarase I inhibition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1325082